Thyrocare Technologies Ltd (THYROCARE) AI Stock Analysis

• Market Cap: ₹70.19B
• Dividend Yield: 2.01%
• Average Volume (3M): 43.23K
• Price to Earnings (P/E): 54.9
• Beta (1Y): 0.39
• Revenue Growth: 22.36%
• EPS Growth: 52.00%
• Country: IN
• Employees: 1,693
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 9.10
• Shares Outstanding: 53,053,898
• 10 Day Avg. Volume: 39,335
• 30 Day Avg. Volume: 43,228
• PEG Ratio: 1.46
• Price to Book (P/B): 7.05
• Price to Sales (P/S): 5.61
• P/FCF Ratio: 26.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: ₹1,518.00 ▲(22.01% Upside)

Thyrocare Technologies Ltd demonstrates strong financial performance with robust revenue growth and effective cash flow management, contributing significantly to the overall score. Technical analysis supports a bullish outlook, although the RSI suggests caution. The high P/E ratio indicates the stock is priced for growth, which may pose a risk if expectations are not met. The absence of recent earnings call insights or corporate events limits additional context.

Thyrocare Technologies Ltd Business Overview & Revenue Model

Company Description

Thyrocare Technologies Ltd (THYROCARE) is a leading diagnostic service provider based in India, specializing in laboratory testing and health check-up services. Founded in 1996, the company operates a vast network of laboratories and collection centers, offering a wide range of tests including pathology, radiology, and wellness check-ups. Thyrocare is known for its cost-effective and efficient services, utilizing advanced technology and automation to deliver accurate results to both individual customers and healthcare providers.

How the Company Makes Money

Thyrocare generates revenue primarily through its diagnostic testing services, which include a variety of blood tests, genetic tests, and health check-up packages. The company operates a B2B model, supplying services to hospitals, clinics, and healthcare providers, which constitutes a significant portion of its revenue. Additionally, Thyrocare offers direct-to-consumer services, where individuals can order tests online or through collection centers. The company benefits from economies of scale due to its centralized laboratory operations, allowing for lower costs per test and competitive pricing. Thyrocare also engages in partnerships with various healthcare organizations and insurance companies, which helps to broaden its customer base and enhance revenue streams. Key factors contributing to its earnings include a strong brand reputation, a broad service portfolio, and an increasing awareness of preventive healthcare among the population.

Thyrocare Technologies Ltd Financial Statement Overview

Summary

Thyrocare Technologies Ltd exhibits strong financial health with consistent revenue growth, solid profitability margins, and a stable balance sheet. The company effectively manages its cash flows, ensuring operational efficiency and strategic investments. While there are areas for improvement, such as optimizing operational costs and managing capital expenditures, the overall financial outlook is positive, supporting future growth and stability.

Income Statement

Thyrocare Technologies Ltd has demonstrated strong revenue growth with a significant increase from 2024 to 2025, indicating robust market positioning. The gross profit margin has improved, reflecting efficient cost management. However, the net profit margin has seen a slight decrease, suggesting increased operational costs or financial expenses. Overall, the income statement shows a healthy trajectory with some areas for cost optimization.

Balance Sheet

The company maintains a solid equity base with an improving equity ratio, indicating financial stability. The debt-to-equity ratio is low, which minimizes financial risk, although there is a small increase in total debt. Return on equity remains strong, highlighting effective use of shareholder funds. The balance sheet reflects a stable financial structure with room for leveraging growth opportunities.

Cash Flow

Operating cash flow has increased, supporting operational sustainability. The free cash flow growth rate is positive, indicating effective capital management. The operating cash flow to net income ratio suggests high-quality earnings. However, capital expenditure remains significant, which may impact future liquidity if not managed carefully. Overall, cash flow statements show a healthy cash position with strategic investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.23B	6.87B	5.72B	5.27B	5.89B	4.95B
Gross Profit	5.62B	4.96B	1.81B	3.63B	4.19B	3.31B
EBITDA	2.21B	2.05B	1.48B	1.31B	2.64B	1.84B
Net Income	1.06B	915.10M	707.60M	644.90M	1.76B	1.13B
Balance Sheet
Total Assets	0.00	6.93B	6.44B	6.33B	6.08B	5.46B
Cash, Cash Equivalents and Short-Term Investments	1.55B	1.92B	1.77B	1.51B	1.39B	1.18B
Total Debt	0.00	246.80M	423.40M	233.10M	207.00M	84.90M
Total Liabilities	-5.47B	1.46B	1.16B	975.00M	810.90M	1.19B
Stockholders Equity	5.47B	5.47B	5.27B	5.34B	5.27B	4.27B
Cash Flow
Free Cash Flow	0.00	1.46B	1.06B	856.60M	755.80M	877.70M
Operating Cash Flow	0.00	1.91B	1.68B	1.29B	1.13B	1.16B
Investing Cash Flow	0.00	-525.20M	-912.80M	-389.90M	-235.70M	-502.30M
Financing Cash Flow	0.00	-1.30B	-848.00M	-861.80M	-894.10M	-615.70M

Thyrocare Technologies Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1244.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THYROCARE, the sentiment is Positive. The current price of 1244.2 is below the 20-day moving average (MA) of 1293.77, below the 50-day MA of 1254.67, and above the 200-day MA of 1005.92, indicating a bullish trend. The MACD of 38.89 indicates Negative momentum. The RSI at 64.80 is Neutral, neither overbought nor oversold. The STOCH value of 66.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:THYROCARE.

Thyrocare Technologies Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
THYROCARE	75 Outperform	₹70.19B	54.89	―	2.01%	22.36%	52.00%
VIJAYA	68 Neutral	₹105.28B	70.08	―	0.20%	16.71%	13.92%
KRSNAA	63 Neutral	₹24.96B	30.99	―	0.38%	13.78%	32.21%
METROPOLIS	61 Neutral	₹105.27B	68.82	―	―	15.41%	5.93%
MOREPENLAB	59 Neutral	₹25.99B	27.84	―	0.43%	2.12%	-25.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Thyrocare Technologies Ltd Corporate Events

Thyrocare Technologies Announces Postal Ballot Notice Publication

Thyrocare Technologies Limited has announced the publication of a notice for a postal ballot in newspapers, as per regulatory requirements. This notice informs stakeholders about the completion of sending postal ballot notices and the e-voting period, which is also available on the company’s website.

Thyrocare Technologies Releases Earnings Call Transcript

Thyrocare Technologies Limited announced the release of the transcript from its earnings conference call held on October 14, 2025. This disclosure is in accordance with regulatory requirements and is available on the company’s website. The call involved discussions with analysts and investors, providing insights into the company’s financial performance and strategic direction. This release is significant for stakeholders as it offers transparency into the company’s operations and future outlook.

Thyrocare Technologies Releases Q2 2025 Financial Results

Thyrocare Technologies Ltd has released its unaudited financial results for the quarter and half-year ending September 30, 2025. The results were published in both Marathi and English newspapers, Navshakti and Business Standard, respectively. The publication of these results is in compliance with the SEBI Listing Regulations, and they are also available on the company’s website. This disclosure is significant for stakeholders as it provides insights into the company’s financial performance and operational efficiency during the specified period.

Thyrocare Seeks Shareholder Approval for New Director Appointment via Postal Ballot

Thyrocare Technologies Limited has announced a postal ballot to seek shareholder approval for the appointment of Mr. Alok Kumar Jagnani as a Non-Executive & Non-Independent Director. The remote e-voting for this resolution will take place from August 28 to September 26, 2025, with results expected by September 29, 2025. This move is part of the company’s ongoing governance and management efforts, potentially impacting its strategic direction and stakeholder engagement.